Trabedersen - Autotelic/Oncotelic

Drug Profile

Trabedersen - Autotelic/Oncotelic

Alternative Names: AP 2/09-DS; AP-12009; AP-2/09; OT-101; OT-201; Personalised dosing TGF-beta antisense; TGF-beta antisense

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antisense Pharma
  • Developer Autotelic; Oncotelic
  • Class Antineoplastics; Oligodeoxyribonucleotides; Thionucleotides
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II/III Malignant melanoma; Pancreatic cancer
  • Preclinical Ovarian cancer
  • No development reported Colorectal cancer
  • Discontinued Anaplastic astrocytoma

Most Recent Events

  • 08 Sep 2017 Preclinical trials in Pancreatic cancer, Ovarian cancer, Glioblastoma and Malignant melanoma (Combination therapy) in USA (IV)
  • 31 Aug 2017 Efficacy and pharmacokinetic data from a phase I/II trial in Pancreatic cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 17 Jul 2017 Oncotelic in-licenses conformationally restricted nucleotide (CRN) technology from Marina Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top